Format

Send to

Choose Destination
Leukemia. 2019 Apr;33(4):1047-1051. doi: 10.1038/s41375-018-0320-9. Epub 2019 Jan 10.

Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma.

Author information

1
Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
2
Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. anna.guidetti@istitutotumori.mi.it.
3
Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy. anna.guidetti@istitutotumori.mi.it.
4
Department of Hematology, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy.
5
Department of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
6
Department of Hematology, Azienda Ospedaliero Universitaria Citta' della Salute e della Scienza di Torino, Torino, Italy.
7
Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
8
Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.
9
Department of Pathology, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy.
PMID:
30631117
DOI:
10.1038/s41375-018-0320-9
Free full text

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for Archivio Istituzionale della Ricerca Unimi
Loading ...
Support Center